Merck & Co., Inc. (NYSE:MRK) Shares Purchased by Doliver Advisors LP

Doliver Advisors LP lifted its stake in Merck & Co., Inc. (NYSE:MRK) by 27.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,106 shares of the company’s stock after purchasing an additional 1,315 shares during the quarter. Doliver Advisors LP’s holdings in Merck & Co., Inc. were worth $519,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Bath Savings Trust Co grew its position in Merck & Co., Inc. by 67.8% in the second quarter. Bath Savings Trust Co now owns 6,799 shares of the company’s stock worth $570,000 after acquiring an additional 2,746 shares during the period. Pensionfund DSM Netherlands purchased a new position in Merck & Co., Inc. in the second quarter worth approximately $5,953,000. Pensionfund Sabic purchased a new position in Merck & Co., Inc. in the second quarter worth approximately $3,941,000. South Texas Money Management Ltd. grew its position in Merck & Co., Inc. by 0.5% in the second quarter. South Texas Money Management Ltd. now owns 645,800 shares of the company’s stock worth $54,150,000 after acquiring an additional 2,952 shares during the period. Finally, Stillwater Investment Management LLC grew its position in Merck & Co., Inc. by 2.6% in the second quarter. Stillwater Investment Management LLC now owns 4,796 shares of the company’s stock worth $402,000 after acquiring an additional 120 shares during the period. 74.95% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently weighed in on the company. Societe Generale set a $105.00 price objective on Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Argus increased their price objective on Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. ValuEngine lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Leerink Swann assumed coverage on Merck & Co., Inc. in a research report on Thursday, August 15th. They issued an “outperform” rating and a $103.00 price objective for the company. Finally, Bank of America began coverage on Merck & Co., Inc. in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 price objective for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $95.13.

MRK opened at $83.59 on Friday. Merck & Co., Inc. has a 52 week low of $70.89 and a 52 week high of $87.35. The business has a fifty day simple moving average of $84.01 and a 200-day simple moving average of $82.77. The firm has a market cap of $212.31 billion, a P/E ratio of 19.26, a P/E/G ratio of 1.80 and a beta of 0.54. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 0.82.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, topping the consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The business had revenue of $12.40 billion during the quarter, compared to analyst estimates of $11.59 billion. During the same period last year, the business posted $1.19 earnings per share. The company’s quarterly revenue was up 14.9% on a year-over-year basis. Sell-side analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: Trading Penny Stocks

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.